Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Liabilities and Shareholders Equity (2020 - 2025)

Bioventus' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $683.6 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 6.1% year-over-year to $683.6 million; the TTM value through Dec 2025 reached $2.8 billion, down 9.74%, while the annual FY2025 figure was $683.6 million, 6.1% down from the prior year.
  • Liabilities and Shareholders Equity reached $683.6 million in Q4 2025 per BVS's latest filing, down from $701.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q4 2022 to a low of $643.1 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $878.0 million, with a median of $793.2 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 147.92% in 2021, then plummeted 41.98% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.2 billion in 2021, then rose by 11.97% to $1.4 billion in 2022, then plummeted by 40.92% to $810.9 million in 2023, then decreased by 10.23% to $728.0 million in 2024, then fell by 6.1% to $683.6 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Liabilities and Shareholders Equity are $683.6 million (Q4 2025), $701.6 million (Q3 2025), and $706.8 million (Q2 2025).